SVRA,Savara Inc. | Healthcare - www.financetom.com

Overview >

Market Cap

590.38M

Revenue (ttm)

n/a

Net Income (ttm)

-95.88M

Shares Out

210.47M

EPS (ttm)

-0.48

PE Ratio

n/a

Forward PE

n/a

Dividend

n/a

Ex-Dividend Date

n/a

Volume

196,962

Open

2.630

Previous Close

2.640

Day's Range

2.600 - 2.820

52-Week Range

2.255 - 5.330

Beta

0.52

Analysts

Buy

Price Target

8.83 (+214.8%)

Earnings Date

May 8, 2025

Description >

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.

The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.

Savara Inc. is headquartered in Austin, Texas.

Latest News >

Gold steadies above five-week lows as market rally pauses

Mar 6, 2019

Spot gold was steady at $1,287.25 per ounce after slipping to $1,280.70 in the previous session, its lowest since January 25.

Mitessh Thakkar on March 6: Buy ITC, Hero Motocorp, L&T Finance Holdings, Siemens

Mar 5, 2019

The latest analysis and commentary by stock market guru Mitessh Thakkar on what is moving the markets today. Check out his top stock recommendations.

Prakash Gaba on March 6: Buy Bharti Infratel & SBI

Mar 6, 2019

The latest analysis and commentary by stock market guru Prakash Gaba on what is moving the markets today.

Here’s why SP Tulsian is positive on NBFC, FMCG & auto stocks

Mar 6, 2019

In an interview to CNBC-TV18, stock market guru SP Tulsian shared his views on individual stocks and market fundamentals.